Clinical trials: Glioma, Malignant
Glioblastoma
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
This research is being determine whether vaccinations with your own immune cells called " dendritic cells " can activate your immune system to fight your brain tumor.
- Trial name
- NCT00576537
- Testing
- Dendritic Cell Immunotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cedars-Sinai Medical Center
Glioblastoma, Anaplastic Astrocytoma
Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly
The study aims to optimize the treatment of elderly subjects (> 65) with anaplastic astrocytoma and glioblastoma. Current treatment policies tend to be no more than palliative.
- Trial name
- Methusalem (NCT01502241)
- Testing
- Temozolomide, Radiotherapy of the partial brain.
- Where
- 23 sites in Germany, Switzerland
- Volunteers
- 412 people
- Sponsor
- Heidelberg University
Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain
Trial of C134 in Patients With Recurrent GBM
The purpose of this project is to obtain safety information in small groups of individuals, scheduled to receive escalating doses of C134, a cancer killing virus (HSV-1) that has been genetically engineered to safely replicate…
- Conditions
- Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain
- Trial name
- C134-HSV-1 (NCT03657576)
- Testing
- C134
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Alabama at Birmingham
Primary Glioblastoma, Glioblastoma Multiforme
LAM561 With RT and TMZ for Adults With Glioblastoma
The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with…
- Trial name
- CLINGLIO (NCT04250922)
- Testing
- LAM561, TMZ, RT
- Where
- 22 sites in France, Israel and 3 more
- Volunteers
- 144 people
- Sponsor
- Laminar Pharmaceuticals
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02839954
- Testing
- anti-MUC1 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Glioblastoma
Phase I Trial of pH Resections of GBM at VA
Glioblastoma is an infiltrating tumor that is difficult to visualize in surgery and on standard images. A special pH (acid-base) related magnetic resonance imaging (MRI) has been developed to better see infiltrating tumor.
- Trial name
- NCT07218367
- Testing
- pH MRI based resection of GBM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Malignant Glioma
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
1. Purpose and objective: 1. To determine the safety and tolerability of palonosetron in the prevention of radiation induced nausea and vomiting (RINV) in primary glioma patients receiving radiation (RT) and concomitant…
- Trial name
- NCT00900757
- Testing
- Palonosetron (PALO)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Malignant Glioma, Ependymoma
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the…
- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT03033992
- Testing
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Children's Oncology Group
Brain Neoplasms
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Extent of resection is a very important prognostic factor affecting survival in individuals diagnosed with a malignant glioma. However, the infiltrative nature of the malignant glioma tumor cells produces indistinct borders…
- Trial name
- NCT00977795
- Testing
- 5-aminolevulinic acid
- Sponsor
- Endeavor Health
Glioma, Malignant
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional…
- Trial name
- FET PET in HGG (NCT06172595)
- Testing
- FET PET
- Where
- 2 sites in Singapore
- Volunteers
- 22 people
- Sponsor
- Singapore General Hospital
Brain and Central Nervous System Tumors
Irinotecan in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent…
- Trial name
- NCT00003301
- Testing
- irinotecan hydrochloride
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioma
Hypofractionated IMRT With Temozolomide for HGG
To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery.
- Trial name
- NCT02082119
- Testing
- Hypofractionated IMRT
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Glial Cell Tumors, Malignant Gliomas
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Currently, there are few effective treatments for the following aggressive brain tumors: glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri, gliosarcoma, or brainstem glioma.
- Conditions
- Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- NCT00879437
- Testing
- Valproic acid, Bevacizumab, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Brain and Central Nervous System Tumors, Thrombocytopenia
Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy
RATIONALE: Studying samples of blood in the laboratory from patients receiving temozolomide may help doctors learn how temozolomide works in the body.
- Trial name
- NCT00471653
- Testing
- temozolomide, comparative genomic hybridization, polymorphism analysis
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma
A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma
To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide in subjects…
- Trial name
- KARE003 (NCT00660283)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kentuckiana Cancer Institute
Malignant Glioma
Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma
The purpose of this study is to determine the toxicity and tolerance of Myocet® in children and adolescents with refractory or relapsed malignant glioma, with a dose diminished of 20% of the dose recommended for adults and a dose…
- Trial name
- MYOCET (NCT02861222)
- Testing
- Doxorubicin
- Where
- 7 sites in France
- Volunteers
- 13 people
- Sponsor
- Central Hospital, Nancy, France
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
This is a multicenter study evaluating the safety and tolerability of increasing doses of Toca 511, a retroviral replicating vector, injected into the resection cavity of patients with Grade III or Grade IV Gliomas who have…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01470794
- Testing
- Toca 511 vector, Toca FC
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Tocagen Inc.
Malignant Glioma
Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
The objective of this study is to determine the survival status of patients enrolled in study GLI01S (all-case observational study).
- Trial name
- NCT02300506
- Testing
- No intervention
- Where
- 2 sites in Japan
- Volunteers
- 507 people
- Sponsor
- Eisai Co., Ltd.
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma
Childhood aggressive gliomas are rare brain tumors with very poor prognosis. Due to the tumor's location and infiltrative nature, surgical removal is not always possible, and even when resection is performed and combined with…
- Trial name
- ADDICT-pedGLIO (NCT04911621)
- Testing
- Dendritic cell vaccination + temozolomide-based chemoradiation, Dendritic cell vaccination +- conventional next-line treatment
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
Pediatric High Risk Gliomas
Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas
Tumours of the brain and of the central nervous system (CNS) are the most common solid tumours in children. Amongst these, gliomas are the most frequent, although this term covers different histological subtypes, the most…
- Trial name
- NCT01574092
- Testing
- Combination of two marketed drugs (irinotecan and cisplatin)
- Where
- Spain
- Volunteers
- 39 people
- Sponsor
- Hospital Sant Joan de Deu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.